Fig. 2: Silencing BCKDK exacerbates DOX-mediated cell death in TNBCs. | Cell Death Discovery

Fig. 2: Silencing BCKDK exacerbates DOX-mediated cell death in TNBCs.

From: Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity

Fig. 2

A Immunoblot and densitometric analysis of BCKDK, total and cleaved Caspase 3, cleaved Caspase 7, total and cleaved PARP, total and phosphorylated ATM Ser 1981 in MDA-MB231 cells transfected with siCON, siBDK#1, or siBDK#2 for 72 h followed by 2 µM DOX or DMSO for 18 h. B, C MDA-MB231 (B) and BT549 (C) cells were transfected with siCON, siBDK#1, or siBDK#2 for 72 h followed by 2 µM DOX or DMSO treatment for 18 h and analyzed for Caspase 3 activity. D, E MDA-MB231 cells transfected with siCON, siBDK#1, or siBDK#2 for 72 h followed by 2 µM DOX or DMSO treatment for 18 h and analyzed for D LDH release in the media, and E metabolic activity measured by CCK8 assay. Quantifications are from three independent experiments. A–D, *within groups (DMSO vs DOX), #between DOX groups (siCON vs siBDK#1 or vs siBDK#2), E, *siCON vs siBDK#2, #siCON+DOX vs siBDK#1+DOX, @siCON+DOX vs siBDK#2+DOX. Data presented as mean ± S.D. Statistical analysis was performed using a two-way ANOVA followed by a Tukey’s multiple comparison test; *p < 0.05, **p < 0.01, ****p < 0.0001 as indicated.

Back to article page